The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Genetic testing to risk stratify patients with CLL and aid in treatment decisions
Thomas Kipps, MD, PhD, UC San Diego Moores Cancer Center, La Jolla, CA, discusses the use of genetic testing to assess the mutational landscape of patients with chronic lymphocytic leukemia (CLL). He highlights how the technique allows the identification of key genes that may influence disease progression and enables clinicians to make more informed decisions regarding appropriate therapies. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
